Indivior and Supernus updated merger disclosures after Supernus investors challenged them, and the filing says claims could delay the deal. Both companies deny wrongdoing and added details to limit delay risk.
The added pages do not report a vote result or a completed merger. Supernus denies wrongdoing, and both companies say the extra details are meant to limit legal costs and delay risk. The complaints could still slow the deal, so this filing alone does not change Indivior's business outlook.
Supernus investors challenged merger disclosures, and the filing says complaints could delay the deal. Supernus denies wrongdoing and added details to limit delay risk. No vote result or deal change is reported, so Supernus's outlook is unchanged.
Follow Indivior Pharmaceuticals, Inc. (INDV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for INDV